270 related articles for article (PubMed ID: 35663306)
1. Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts.
Yang S; Wang X; Xiao W; Xu Z; Ye H; Sha X; Yang H
Front Endocrinol (Lausanne); 2022; 13():891922. PubMed ID: 35663306
[TBL] [Abstract][Full Text] [Related]
2. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
[No Abstract] [Full Text] [Related]
3. Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy.
Wang X; Ye H; Yang S; Sha X; Wang X; Zhang T; Chen R; Xiao W; Yang H
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563653
[TBL] [Abstract][Full Text] [Related]
4. Gypenosides Protect Orbital Fibroblasts in Graves Ophthalmopathy via Anti-Inflammation and Anti-Fibrosis Effects.
Li H; Ma C; Liu W; He J; Li K
Invest Ophthalmol Vis Sci; 2020 May; 61(5):64. PubMed ID: 32462203
[TBL] [Abstract][Full Text] [Related]
5. Ceruloplasmin regulating fibrosis in orbital fibroblasts provides a novel therapeutic target for Graves' orbitopathy.
Cao J; Qi X; Wang N; Chen Y; Xie B; Ma C; Chen Z; Xiong W
J Endocrinol Invest; 2023 Oct; 46(10):2005-2016. PubMed ID: 36849849
[TBL] [Abstract][Full Text] [Related]
6. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
[No Abstract] [Full Text] [Related]
7. Lutein targeting orbital fibroblasts attenuates fibrotic and inflammatory effects in thyroid-associated ophthalmopathy.
Hei X; Lin B; Wu P; Li X; Mao Z; Huang S; Zhang F; Zhou M; Ke Y; Yang H; Huang D
Exp Eye Res; 2023 Jul; 232():109515. PubMed ID: 37207866
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
9. Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy.
Jang SY; Choi SH; Kikkawa D; Lee EJ; Yoon JS
PLoS One; 2021; 16(8):e0255344. PubMed ID: 34383782
[TBL] [Abstract][Full Text] [Related]
10. JNK and p38 Inhibitors Prevent Transforming Growth Factor-β1-Induced Myofibroblast Transdifferentiation in Human Graves' Orbital Fibroblasts.
Hou TY; Wu SB; Kau HC; Tsai CC
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799469
[TBL] [Abstract][Full Text] [Related]
11. Potential Therapeutic Activity of Berberine in Thyroid-Associated Ophthalmopathy: Inhibitory Effects on Tissue Remodeling in Orbital Fibroblasts.
Diao J; Chen X; Mou P; Ma X; Wei R
Invest Ophthalmol Vis Sci; 2022 Sep; 63(10):6. PubMed ID: 36094643
[TBL] [Abstract][Full Text] [Related]
12. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
[No Abstract] [Full Text] [Related]
13. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts.
Tsai CC; Wu SB; Kau HC; Wei YH
Sci Rep; 2018 May; 8(1):7276. PubMed ID: 29739987
[TBL] [Abstract][Full Text] [Related]
14. Curcumin Suppresses TGF-β1-Induced Myofibroblast Differentiation and Attenuates Angiogenic Activity of Orbital Fibroblasts.
Yu WK; Hwang WL; Wang YC; Tsai CC; Wei YH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202024
[TBL] [Abstract][Full Text] [Related]
15. The Potential Role of Osteopontin in the Pathogenesis of Graves' Ophthalmopathy.
Lou H; Wu LQ; Wang H; Wei RL; Cheng JW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):18. PubMed ID: 34546326
[TBL] [Abstract][Full Text] [Related]
16. Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.
Wu SB; Hou TY; Kau HC; Tsai CC
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680057
[TBL] [Abstract][Full Text] [Related]
17. Crocin Inhibits Orbital Fibroblasts Fibrosis in Thyroid-Associated Ophthalmopathy.
Xu S; Mao H
Curr Eye Res; 2024 Mar; 49(3):330-337. PubMed ID: 37982317
[TBL] [Abstract][Full Text] [Related]
18. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
[TBL] [Abstract][Full Text] [Related]
19. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
[TBL] [Abstract][Full Text] [Related]
20. Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.
Guo Y; Li H; Chen X; Yang H; Guan H; He X; Chen Y; Pokharel S; Xiao H; Li Y
J Clin Endocrinol Metab; 2020 Jun; 105(6):1906-17. PubMed ID: 32249902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
